News Home

Mersana Therapeutics Inc (MRSN) Stock: Do Analysts Think You Should Sell?

Wednesday, December 08, 2021 11:16 AM | InvestorsObserver Analysts
Mersana Therapeutics Inc (MRSN) Stock: Do Analysts Think You Should Sell?

Analysts who follow Mersana Therapeutics Inc (MRSN) on average expect it to climb 293.55% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy. That average rating earns the stock an Analyst Ranking of 63, which means it ranks higher than 63 of stocks, based on data compiled by InvestorsObserver.

Overall Score - 4.7
Wall Street analysts are rating MRSN a Strong Buy today. Find out what this means to you and get the rest of the rankings on MRSN!

Why are Analyst Ratings Important?

Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers. InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.

What's Happening With Mersana Therapeutics Inc Stock Today?

Mersana Therapeutics Inc (MRSN) stock has risen 1.94% while the S&P 500 is down -0.17% as of 11:09 AM on Wednesday, Dec 8. MRSN is up $0.12 from the previous closing price of $6.19 on volume of 245,440 shares. Over the past year the S&P 500 is higher by 26.38% while MRSN is down -74.52%. MRSN lost -$2.14 per share the over the last 12 months. Click Here to get the full Stock Report for Mersana Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App